

## Title (en)

Pharmaceutical compositions comprising tachykinins antagonists and a serotonin reuptake inhibitor.

## Title (de)

Pharmazeutische Zusammenstellungen aus Tachykinin Antagonisten und einen Serotonin-Wiederaufnahme Hemmer

## Title (fr)

Compositions pharmaceutiques contenant des antagonistes de tachykinines et un inhibiteur de la reprise de sérotonine

## Publication

**EP 1454901 B1 20080903 (EN)**

## Application

**EP 04076650 A 20001005**

## Priority

- EP 00969414 A 20001005
- GB 9923748 A 19991007

## Abstract (en)

[origin: WO0125219A2] The present invention relates to piperazine derivatives of formula (I) wherein R represents a halogen atom or a C1-4 alkyl group; R1 represents hydrogen or a C1-4 alkyl group; R2 represents hydrogen, a C1-4 alkyl, C2-6 alkenyl or a C3-7 cycloalkyl group; or R1 and R2 together with nitrogen and carbon atom to which they are attached respectively represent a 5-6 membered heterocyclic group; R3 represents a trifluoromethyl, a C1-4 alkyl, a C1-4 alkoxy, a trifluoromethoxy or a halogen group; R4 represents hydrogen, a (CH<sub>2</sub>)<sub>q</sub>R7 or a (CH<sub>2</sub>)<sub>r</sub>CO(CH<sub>2</sub>)<sub>p</sub>R7 group; R5 represents hydrogen, a C1-4 alkyl or a COR6 group; R6 represents hydrogen, hydroxy, amino, methylamino, dimethylamino a 5 membered heteroaryl group containing 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen or a 6 membered heteroaryl group containing 1 to 3 nitrogen atoms; R7 represents hydrogen, hydroxy or NR8R9 wherein R8 and R9 represent independently hydrogen or C1-4 alkyl optionally substituted by hydroxy, or by amino; R10 represents hydrogen, a C1-4 alkyl I group or R10 together with R2 represents a C3-7 cycloalkyl group; m is zero or an integer from 1 to 3; n is zero or an integer from 1 to 3; both p and r are independently zero or an integer from 1 to 4; q is an integer from 1 to 4; provided that, when R1 and R2 together with nitrogen and carbon atom to which they are attached respectively represent a 5 to 6 membered heterocyclic group, i) m is 1 or 2; ii) when m is 1, R is not fluorine and iii) when m is 2, the two substituents R are not both fluorine, and pharmaceutically acceptable salts and solvates thereof.

## IPC 8 full level

**C07D 241/04** (2006.01); **A61K 31/495** (2006.01); **A61K 31/496** (2006.01); **A61P 1/04** (2006.01); **A61P 11/06** (2006.01); **A61P 25/04** (2006.01); **A61P 25/06** (2006.01); **A61P 25/18** (2006.01); **A61P 25/22** (2006.01); **A61P 25/24** (2006.01); **A61P 25/28** (2006.01); **A61P 25/30** (2006.01); **A61P 29/00** (2006.01); **C07D 401/06** (2006.01); **C07D 403/06** (2006.01)

## CPC (source: EP KR US)

**A61K 31/135** (2013.01 - EP US); **A61K 31/196** (2013.01 - EP US); **A61K 31/495** (2013.01 - EP US); **A61K 31/496** (2013.01 - EP KR US); **A61P 1/04** (2018.01 - EP); **A61P 1/08** (2018.01 - EP); **A61P 11/06** (2018.01 - EP); **A61P 25/00** (2018.01 - EP); **A61P 25/04** (2018.01 - EP); **A61P 25/06** (2018.01 - EP); **A61P 25/18** (2018.01 - EP); **A61P 25/22** (2018.01 - EP); **A61P 25/24** (2018.01 - EP); **A61P 25/28** (2018.01 - EP); **A61P 25/30** (2018.01 - EP); **A61P 25/32** (2018.01 - EP); **A61P 25/34** (2018.01 - EP); **A61P 25/36** (2018.01 - EP); **A61P 29/00** (2018.01 - EP); **C07D 241/04** (2013.01 - EP KR US); **C07D 401/06** (2013.01 - EP US); **C07D 403/06** (2013.01 - EP US)

## C-Set (source: EP US)

1. **A61K 31/135 + A61K 2300/00**
2. **A61K 31/196 + A61K 2300/00**
3. **A61K 31/495 + A61K 2300/00**

## Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

## Designated extension state (EPC)

SI

## DOCDB simple family (publication)

**WO 0125219 A2 20010412; WO 0125219 A3 20011213**; AR 025975 A1 20021226; AR 077414 A2 20110824; AT E270664 T1 20040715; AT E407125 T1 20080915; AT E435215 T1 20090715; AU 768780 B2 20040108; AU 7913900 A 20010510; BR 0014541 A 20020917; CA 2386515 A1 20010412; CA 2386515 C 20110607; CN 100413850 C 20080827; CN 1391564 A 20030115; CO 5251467 A1 20030228; CY 1110104 T1 20150114; CY 1110172 T1 20150114; CZ 20021166 A3 20021113; CZ 302340 B6 20110323; DE 60012031 D1 20040812; DE 60012031 T2 20050707; DE 60040176 D1 20081016; DE 60042501 D1 20090813; DK 1218359 T3 20041018; DK 1454901 T3 20090112; DK 1460066 T3 20091102; EP 1218359 A2 20020703; EP 1218359 B1 20040707; EP 1454901 A1 20040908; EP 1454901 B1 20080903; EP 1460066 A1 20040922; EP 1460066 B1 20090701; ES 2222927 T3 20050216; ES 2312917 T3 20090301; ES 2329130 T3 20091123; GB 9923748 D0 19991208; HK 1052506 A1 20030919; HK 1052506 B 20081219; HK 1065798 A1 20050304; HK 1066537 A1 20050324; HU P0203136 A2 20030228; HU P0203136 A3 20030328; IL 148964 A0 20021110; IL 148964 A 20070211; JP 2003511377 A 20030325; JP 4776844 B2 20110921; KR 100817373 B1 20080327; KR 100857671 B1 20080908; KR 20020038800 A 20020523; KR 20070112308 A 20071122; MX PA02003515 A 20020902; MY 130907 A 20070731; NO 20021637 D0 20020405; NO 20021637 L 20020606; NO 323776 B1 20070702; NZ 518144 A 20040430; NZ 531127 A 20051125; PE 20010741 A1 20010718; PL 201191 B1 20090331; PL 356261 A1 20040628; PT 1218359 E 20041029; PT 1454901 E 20081212; PT 1460066 E 20090910; SI 1218359 T1 20050228; SI 1454901 T1 20090228; SI 1460066 T1 20091231; TN SN00194 A1 20051110; TR 200200936 T2 20020722; TW I225485 B 20041221; US 2003028021 A1 20030206; US 2004048862 A1 20040311; US 2004209893 A1 20041021; US 2006122192 A1 20060608; US 2008249108 A1 20081009; US 6642240 B2 20031104; US 6951861 B1 20051004; US 7071196 B2 20060704; US 7345041 B2 20080318; US 7625904 B2 20091201; ZA 200202589 B 20030827

## DOCDB simple family (application)

**EP 0009722 W 20001005**; AR P000105284 A 20001006; AR P100102567 A 20100715; AT 00969414 T 20001005; AT 04076632 T 20001005; AT 04076650 T 20001005; AU 7913900 A 20001005; BR 0014541 A 20001005; CA 2386515 A 20001005; CN 00815860 A 20001005; CO 00075822 A 20001005; CY 081101376 T 20081127; CY 091100969 T 20090918; CZ 20021166 A 20001005; DE 60012031 T 20001005; DE 60040176 T 20001005; DE 60042501 T 20001005; DK 00969414 T 20001005; DK 04076632 T 20001005; DK 04076650 T 20001005; EP 00969414 A 20001005; EP 04076632 A 20001005; EP 04076650 A 20001005; ES 00969414 T 20001005; ES 04076632 T 20001005; ES 04076650 T 20001005; GB 9923748 A 19991007; HK 03104740 A 20030703; HK 04108748 A 20041106; HK 04109454 A 20041201; HU P0203136 A 20001005; IL 14896400 A 20001005; IL 14896402 A 20020401; JP 2001528165 A 20001005; KR 20027004438 A 20020406; KR 20077026231 A 20071112; MX PA02003515 A 20001005; MY PI20004668 A 20001005; NO 20021637 A 20020405;

NZ 51814400 A 20001005; NZ 53112700 A 20001005; PE 0010682000 A 20001006; PL 35626100 A 20001005; PT 00969414 T 20001005;  
PT 04076632 T 20001005; PT 04076650 T 20001005; SI 200030492 T 20001005; SI 200031010 T 20001005; SI 200031037 T 20001005;  
TN SN00194 A 20001006; TR 200200936 T 20001005; TW 89121014 A 20001007; US 19017002 A 20020703; US 33426706 A 20060118;  
US 63782503 A 20030808; US 83883804 A 20040504; US 8996402 A 20020508; US 95584707 A 20071213; ZA 200202589 A 20020403